Fig. 3: Efficacy of the combination therapy regimen in NSCLC PDX mouse models.

a In all trials, treatment with the combination therapy regimen (cabozantinib, plerixafor, afatinib, and etoricoxib) was highly effective in preventing tumor propagation and tumor out-growth achieving stable disease and partial response as best response criteria in all experiments. Stable body weight throughout the complete trials indicates a distinguished safety profile of the applied combination regimen. Therapy resistance profiles of lung PDX models per RECIST are indicated and visualized by the red circle for progressive disease (PD), yellow circle for stable disease (SD), and green circle for partial and complete response (PR, CR). All groups were conducted with n = 3 animals, except for the combination therapy of Lu7406 which was conducted as single a mouse trial (n = 1). b The experiment in Lu7414 with single compounds alone versus the combination therapy regimen reveals a superior effect of the low dose combination therapy. All groups were conducted with n = 3 animals, except for the combination therapy of Lu7414 which was conducted in a trial with two mice (n = 2). Error bars represent the standard deviation within each group with n ≥ 3. End of treatment cycles are indicated by a vertical dotted line.